Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesRisk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population
International Clinical Psychopharmacology, 06/25/09
Duncan EJ et al. - Treatment with risperidone or haloperidol was associated with a more favorable lipid profile than with olanzapine or quetiapine.
Methods- Computerized, retrospective, nonrandomized, case-control analysis of 6331 patients receiving antipsychotics.
- For each patient, the first prescription for at least 60 continuous days for four antipsychotics [haloperidol (HALD), olanzapine (OLANZ), quetiapine (QUET), or risperidone (RISP)] was analyzed for total cholesterol, low-density lipoprotein, high-density lipoprotein (HDL), and triglycerides (TGL).
- Mean HDL was lower during OLANZ treatment than with RISP (P = 0.03) or QUET (P = 0.001).
- TGL were higher during OLANZ (P = 0.0007) or QUET treatment (P = 0.006) than RISP.
- percentage of participants having abnormal cholesterol (P = 0.0003), low-density lipoprotein (P = 0.001), or TGL (P = 0.0001) during medication were in the order: OLANZ > QUET > RISP > HALD.
- For HDL, the results were less robust but the percentage of participants were in the order: OLANZ>RISP = HALD = QUET.
- There was a greater risk of developing new HDL abnormality with OLANZ than RISP (P<0.05).
Today in Anxiety...keeping you current
Receive free subspecialty "5-minute updates" via email
An algorithm for the pharmacological treatment of depression
Acta Psychiatrica Scandinavica, 11/04/09
Estimation of clonazepam abuse liability: a new method using a reimbursed drug database
International Clinical Psychopharmacology, 10/20/09
Impulsivity, personality and bipolar disorder
European Psychiatry , 11/06/09
Today in Mood Disorders...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Clinical trials support new algorithm for treating pediatric bipolar mania
Current Psychiatry, 11/16/09
Today in Neuro/Psych Pharmacol...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Today in Other Psychiatry...keeping you current
Receive free subspecialty "5-minute updates" via email
Is Monotherapy as Good as Polypharmacy in Long-Term Treatment of Bipolar Disorder
Canadian Journal of Psychiatry, 11/16/09
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
Asenapine versus olanzapine in acute mania: a double-blind extension study
Bipolar Disorders, 10/22/09
Sponsor
Article Search
Sponsor